Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if concentration-controlled ribavirin dosing can
achieve a targeted level of plasma exposures and if it appears safe and effective compared
with standard weight-based ribavirin dosing. Forty, previously treatment-naive participants
with genotype 1 disease will be randomized to receive concentration-guided or standard
weight-based ribavirin. Peginterferon alfa 2a,ribavirin, and telaprevir will be provided
through the study.
Phase:
Phase 4
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)